title: Factors contributing to the overall survival in patients with hepatocellular carcinoma treated by sorafenib.
abstract: OBJECTIVE
  In both SHARP and Asia-Pacific Study, sorafenib was proved to improve the overall survival of the patients with hepatocellular carcinoma. However, factors contributing to the improvement of overall survival of the patients treated by sorafenib have not been fully evaluated. In this study, patient-derived, background liver disease-derived and tumor-derived factors before treatment were evaluated whether they have contributed to the improvement of the overall survival.
  
  
  METHODS
  Forty-seven cases with HCC treated by sorafenib between Sept 2009 and Feb 2011 were included in this analysis. The survival of these cases was analyzed by Kaplan-Meier Method. Factors used for univariate analysis were two patient-derived parameters, two background liver disease-derived, five tumor-derived. Factors related to the over-all survival were analyzed by multivariate analysis using Cox regression model.
  
  
  RESULTS
  In the multivariate analysis, only background liver disease-derived parameter Child-Pugh class A vs. B, (p=0.007, HR=0.21 (0.07-0.65)) was significant. No other parameters including tumor-derived factors were statistically significant by multivariate analysis.
  
  
  CONCLUSIONS
  We undertook the statistical analysis on the three categories. Surprisingly, no tumor derived parameter contributed to the overall survival. Background liver disease-derived parameter rather than tumor-derived parameter was found to define the prognosis of patients with advanced HCC treated by sorafenib.
authors.affiliation: Department of Gastroenterology, Yamanashi Central Hospital, Yamanashi, Japan. y-tsukui0908@ych.pref.yamanashi.jp
authors.forename: Yuya
authors.initials: Y
authors.lastname: Tsukui
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Mochizuki
authors.forename: Yuji
authors.initials: Y
authors.lastname: Hoshino
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kawakami
authors.forename: Toru
authors.initials: T
authors.lastname: Kuno
authors.forename: Yoshimitsu
authors.initials: Y
authors.lastname: Fukasawa
authors.forename: Fumihiko
authors.initials: F
authors.lastname: Iwamoto
authors.forename: Sumio
authors.initials: S
authors.lastname: Hirose
authors.forename: Takashi
authors.initials: T
authors.lastname: Yoshida
authors.forename: Kenji
authors.initials: K
authors.lastname: Hosoda
authors.forename: Youji
authors.initials: Y
authors.lastname: Suzuki
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Hosoda
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Kojima
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Hirose
authors.forename: Kuniaki
authors.initials: K
authors.lastname: Shindou
authors.forename: Masanori
authors.initials: M
authors.lastname: Matsuda
authors.forename: Syoji
authors.initials: S
authors.lastname: Yagawa
authors.forename: Akio
authors.initials: A
authors.lastname: Tawara
authors.forename: Masashi
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Konishi
authors.forename: Takahisa
authors.initials: T
authors.lastname: Yamazaki
authors.forename: Seiichiro
authors.initials: S
authors.lastname: Takahashi
authors.forename: Hideki
authors.initials: H
authors.lastname: Fuji
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Enomoto
authors.forename: Masao
authors.initials: M
authors.lastname: Omata
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D007564:Japan; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D016016:Proportional Hazards Models; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D012189:Retrospective Studies; D000077157:Sorafenib; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib